These mutations can also emerge during treatment of EGFRM+ NSCLC with EGFR-TKIs and can cause secondary TKI-resistance to these drugs, given their capability of constitutively activating effectors downstream of EGFR [49,149]. Here, EGFR is linked to non-small cell lung carcinoma.